Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
261. |
ECCT/24/02/02 | Sabin 003 A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults |
Principal Investigator(s) 1. Prof. Videlis Nduba Nzioka Site(s) in Kenya KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya |
23-04-2024 |
View |
262. |
ECCT/24/10/06 | A5409 A Phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) |
18-11-2025 |
View |
263. |
ECCT/24/03/01 | RAD-TB A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis |
Principal Investigator(s) 1. Dr Josphat Kosgei Kosgei Site(s) in Kenya Kenya medical research institute/ Walter Reed program KERICHO |
26-11-2024 |
View |
264. |
ECCT/18/12/01 | study to determine if a new malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants. A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya. |
Principal Investigator(s) 1. Mainga Hamaluba Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
19-03-2019 |
View |
265. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months) |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
09-02-2016 |
View |
266. |
ECCT/14/02/03 | A Phase 1/2 Randomized, Double-Blind, Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus pneumoniae Whole Cell Vaccine Formulated with Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers (12-15 Months of Age) |
Principal Investigator(s) 1. Nekoye Namungu Otsyula 2. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute (KEMRI)/Walter Reed Project, Kombewa Clinical Research Center |
14-02-2014 |
View |
267. |
ECCT/23/11/04 | AUB Study A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy. |
Principal Investigator(s) 1. Dr Alice Kaaria Site(s) in Kenya Kenyatta National Hospital (KNH) |
15-04-2024 |
View |
268. |
ECCT/25/07/01 | FIH Study of CLY-124 A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county) 2. Victoria Biomedical Research Institute [VIBRI] (Kisumu county) |
18-12-2025 |
View |
269. |
ECCT/25/08/09 | First-in-human (FIH) study A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Dr Lucas Tina Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute [VIBRI] (Kisumu county) 2. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county) |
17-09-2026 |
View |
270. |
ECCT/26/06/01 | SANDLY A Phase 1, Multi-Site, Double-Blinded, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Leishmania major LmCen -/- vaccine in healthy Kenyan and Brazilian Adults (SANDFLY) |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya KEMRI WRP CRC KERICHO |
08-11-2026 |
View |